AUS
NZ
UK
CA
USA
IND
Healt
ASX 200 Watch: Can PolyNovo’s Momentum Sustain in the Healthcare Sector?
September 12, 2025 04:41 PM AEST| By SamHighlights,PolyNovo shows renewed strength in recent trading sessions,Elevated valuation raises questions on future growth expectations,Healthcare innovation driving investor focus on performance,The,ASX 200,has often been a stage where healthcare in...
A Shifting Story for Nanosonics
September 11, 2025 07:12 PM AEST| By SamHighlights,Nanosonics faces market pressure despite earnings growth,Shareholder sentiment shaped by fundamentals and outlook,Broader ASX dynamics influence investor confidence,Nanosonics (ASX:NAN), a medical technology company best known for its infe...
Doctor Care Anywhere (ASX:DOC)
September 11, 2025 06:36 PM AEST| By SamHighlights,Doctor Care Anywhere (ASX:DOC) faces scrutiny despite strong share movement,Company valuation lags peers in healthcare services space,Future revenue outlook raises critical questions,The,ASX stock market,continues to generate headlines as...
Cleo Diagnostics & the Cash Runway Question: What Investors Should Know ASX 200
September 11, 2025 06:29 PM AEST| By SamHighlights,Cleo Diagnostics’ position under focus amid cash runway discussions,Biotech firms balance growth ambition with funding challenges,Broader insights for investors across the ASX stock market,The,ASX stock market,is home to companies ranging...
Who Owns Ansell (ASX:ANN)? Exploring Institutional Power in the ASX 200 Landscape
September 11, 2025 06:11 PM AEST| By SamHighlights,Ansell’s ownership is dominated by institutional investors,Broader market dynamics influence decision-making power,Public and insider stakes shape long-term governance,The role of institutional ownership in shaping corporate direction is i...
Health Sector Pressure Leads ASX Decline
September 11, 2025 04:03 PM AEST| By SamHighlights,ASX health sector dragged market lower,Wall Street strength lifted global sentiment,AI-linked stocks attracted major attention,The,ASX 200,began the session under pressure as health companies weighed heavily on the broader index. Among tho...
ASX 200 Spotlight: 4DMedical (ASX:4DX) Redefines Lung Imaging with Breakthrough Technology
September 11, 2025 03:50 PM AEST| By SamHighlights,4DMedical gains traction with regulatory approval in the US,Cutting-edge imaging transforms how lungs are examined globally,Rising interest reflects biotechnology’s growing role in the,ASX stock market,The,ASX 200,continues to showcase inn...
PolyNovo Strengthens Chair Stake Amid ASX 200 Attention: Insights into Recent Share Movements
September 11, 2025 01:18 PM AEST| By SamPolyNovo chair increases shareholding, highlighting active insider involvement and ASX 200 positioning.
A Deep Dive into Healthcare Innovation and Market Strength within the ASX 200
September 11, 2025 10:13 AM AEST| By SamResMed (ASX:RMD) leads in healthcare innovation with devices and SaaS solutions, securing its role within the ASX 200 and shaping long-term sector resilience.
ASX 200 Spotlight: Ramsay Health Care Faces Questions as Biotech
September 10, 2025 03:57 PM AEST| By SamHighlights,ASX queries Ramsay Health Care after post-results market reaction,Biotech sector sees strategic updates and funding developments,Healthcare and life sciences firms in focus ahead of AGM season,The,ASX 200,often captures the mood of the bro...
Pathkey.AI (ASX:PKY) Expands TrialKey Insights: Transforming Clinical Trial Predictions
September 09, 2025 04:07 PM AEST| By SamHighlights,Pathkey.AI (ASX:PKY) strengthens its TrialKey platform with fresh validations.,Clinical trial predictions align with real-world biotech outcomes.,Broader applications expand to insurers, biotech innovators, and trial sponsors.,In the fast-...
OncoSil Medical Ltd’s New ASX Quotation What It Means for the ASX 200 Landscape
September 09, 2025 03:32 PM AEST| By SamHighlights,OncoSil Medical Ltd announces quotation of new securities on the ASX.,The move strengthens the company’s operational and financial strategy.,Investors explore the wider impact across the ASX stock market.,The Australian Securities Exchange...
Telix Surges While Broader ASX 200 Market Softens
September 09, 2025 02:46 PM AEST| By SamHighlights,Telix (ASX:TLX) advances on regulatory progress in the healthcare sector,BHP (ASX:BHP) navigates settlement obligations linked to international litigation,Life360 (ASX:360) continues its growth momentum within the technology space,The,ASX...
Biotech Stocks on the ASX: A Deep Guide for 2025
September 08, 2025 04:07 PM AEST| By Team Kalkine MediaAustralia’s biotechnology sector has grown from a niche space into a bona fide growth engine for the local market. From blood-plasma therapeutics to radiopharmaceuticals, implantable medical devices, wound-regeneration scaffolds, and rare-disease dru...
How 4DMedical’s Imaging Innovation Expands Across Hospitals and Screening Programs with ASX 200 Relevance
September 08, 2025 03:56 PM AEST| By Sam4DMedical (ASX:4DX) expands its lung imaging technology across hospitals and global screening programs, enhancing early detection, preventive healthcare, and positioning itself as a leader in respiratory innovation.
Alterity Therapeutics Placement Reframes Liquidity Across All Ordinaries
September 08, 2025 03:41 PM AEST| By SamHighlights,Short-selling backdrop set against a fresh equity placement by Alterity Therapeutics (ASX:ATH),Plain-English view of ATH434, pipeline priorities, and planned use of proceeds,Practical questions for tracking short interest, borrow supply, a...
CSL (ASX:CSL) in Focus A Deep Dive into Its Role in Healthcare and the ASX 200 Today
September 08, 2025 02:47 PM AEST| By SamHighlights,CSL anchors the healthcare space within the S&P/ASX 200 index.,The company operates through CSL Behring, CSL Seqirus, and CSL Vifor.,Strong global presence across plasma therapies, vaccines, and renal treatments.,Prominent inclusion among...
Imagion Biosystems (ASX:IBX) Advances MagSense Imaging Agent as Part of Phase 2 HER2 Breast Cancer Trial
September 08, 2025 01:55 PM AEST| By SamImagion Biosystems (ASX:IBX) advances MagSense imaging agent manufacturing for Phase 2 HER2 breast cancer trial, strengthening biotech presence in the ASX 200 and Australian stock market.
Memphasys (ASX:MEM) Expands Felix Fertility Device Reach Across MENA: A Boost for ASX 200 Market Dynamics
September 08, 2025 01:18 PM AEST| By SamMemphasys secures strategic MENA distribution for its Felix device, highlighting growth potential in ASX 200 landscape and global fertility technology sector.
All Ordinaries EZZ Life Science (ASX:EZZ) Faces Market Pressure
September 07, 2025 09:02 PM AEST| By SamHighlights,EZZ Life Science Holdings reported earnings that show a disconnect between statutory and free flow.,Share dilution reduced earnings per share strength despite reported figures.,Concerns extend beyond a single reporting period, reflecting b...
Advertise your brand on Kalkine Media